Clinical Features and Prognosis of CD20 Negative Aggressive B-Cell Non-Hodgkins Lymphoma

Cluster designation (CD) 20 antigen is expressed on most B-cell lymphomas and serves as a therapeutic target for rituximab. A small minority of aggressive B-cell lymphomas, predominantly plasmablastic variants, do not express CD 20. We systematically reviewed all cases of aggressive B-cell lymphomas diagnosed at our institution over a period of 13 years. Of the 232 cases, 7 did not express CD 20. Five of these were plasmablastic lymphomas while two were unclassifiable B-cell lymphomas. While most of the plasmablastic lymphomas responded to chemotherapy, patients with unclassifiable lymphomas were primarily refractory or relapsed soon after chemotherapy.

Download Full-text

Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30 + anaplastic B-cell subtypes exhibit distinct clinical features

Annals of Oncology ◽

10.1023/a:1011195708834 ◽

2001 ◽

Vol 12 (6) ◽

pp. 853-858 ◽

Cited By ~ 17

Author(s):

B. Maes ◽

A. Anastasopoulou ◽

J.C. Kluin-Nelemans ◽

I. Teodorovic ◽

R. Achten ◽

...

Keyword(s):

T Cell ◽

B Cell ◽

Clinical Features ◽

B Cell Lymphomas ◽

Large B Cell

Download Full-text

SENSITIVITY OF DRUG-RESISTANT B-CELL LINES FROM AIDS-RELATED NON-HODGKINS-LYMPHOMA TO NEWLY SYNTHESIZED PODOPHYLLOTOXIN DERIVATIVES AND AZA-ALKYLLYSOPHOSPHOLIPIDS - ENHANCED SENSITIZATION BY PRETREATMENT WITH INTERFERON-GAMMA

International Journal of Oncology ◽

10.3892/ijo.4.6.1203 ◽

1994 ◽

Author(s):

A DEMIDEM ◽

C BROQUET ◽

JM MENCIAHUERTA ◽

SZ SALAHUDDIN ◽

T LAM ◽

...

Keyword(s):

B Cell ◽

Cell Lines ◽

Interferon Gamma ◽

Drug Resistant ◽

Hodgkins Lymphoma ◽

Non Hodgkins Lymphoma ◽

Podophyllotoxin Derivatives

Download Full-text

Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.02.007 ◽

2018 ◽

Vol 18 (4) ◽

pp. 297-299

Author(s):

Vittorio Stefoni ◽

Alessandro Broccoli ◽

Lisa Argnani ◽

Elena Sabattini ◽

Michele Cavo ◽

...

Keyword(s):

B Cell ◽

Treatment Outcomes ◽

Clinical Features ◽

B Cell Lymphomas

Download Full-text

Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

Cancer Cell ◽

10.1016/j.ccr.2012.09.003 ◽

2012 ◽

Vol 22 (4) ◽

pp. 506-523 ◽

Cited By ~ 187

Author(s):

Xinwei Zhang ◽

Xiaohong Zhao ◽

Warren Fiskus ◽

Jianhong Lin ◽

Tint Lwin ◽

...

Keyword(s):

Histone Modification ◽

B Cell ◽

Therapeutic Target ◽

B Cell Lymphomas

Download Full-text

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma - Results of a Multicenter Prospective Randomised Phase II Study.

Blood ◽

10.1182/blood.v108.11.4704.4704 ◽

2006 ◽

Vol 108 (11) ◽

pp. 4704-4704 ◽

Cited By ~ 2

Author(s):

Mathias Witzens-Harig ◽

Manfred Hensel ◽

Johann W. Schmier ◽

Kai Neben ◽

Axel Benner ◽

...

Keyword(s):

Maintenance Therapy ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Aggressive Lymphoma ◽

Pharmacokinetic Data ◽

Hodgkins Lymphoma ◽

Rituximab Maintenance ◽

Mediastinal Lymphoma ◽

Non Hodgkins Lymphoma

Abstract Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m2) every 3 months for 2 years. Patients after first line therapy as well as relapse patients were included in the study. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. So far 162 patients (pts) with CD20+ B-cell Non-Hodgkins-Lymphoma were enrolled in this trial. Histological subtypes included diffuse large cell lymphoma (69 pts), follicular lymphoma (41 pts), mantle cell lymphoma (18 pts), primary mediastinal lymphoma (15 pts), marginal zone lymphoma (9 pts), Burkitt’s lymphoma (3 pts), immunocytoma (2 pts), primary intestinal lymphoma (1 pt), hairy cell leukemia (1 pt), chronic lymphocytic leukemia (1 pt) and unclassified B-cell lymphoma (2 pts). No severe adverse events were observed during rituximab maintenance therapy. We conclude that rituximab maintenance therapy is feasable, safe and well tolerated in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. Results including event free survival and overall survival for the observation group and for the maintenance therapy group will be presented.

Download Full-text

Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.17524 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 17524-17524 ◽

Cited By ~ 1

Author(s):

M. Witzens-Harig ◽

M. Hensel ◽

J. W. Schmier ◽

K. Neben ◽

A. Benner ◽

...

Keyword(s):

Maintenance Therapy ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Aggressive Lymphoma ◽

Pharmacokinetic Data ◽

Hodgkins Lymphoma ◽

Rituximab Maintenance ◽

Mediastinal Lymphoma ◽

Non Hodgkins Lymphoma

17524 Background: Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. Methods: To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m2) every 3 months for 2 years. Patients after first line therapy as well as relapse patients were included in the study. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. Results: So far 124 patients (pts) with CD20+ B-cell Non-Hodgkins-Lymphoma were enrolled in this trial. Histological subtypes included diffuse large cell lymphoma (55 pts), follicular lymphoma (24 pts), mantle cell lymphoma (16 pts), primary mediastinal lymphoma (12 pts), marginal zone lymphoma (8 pt), Burkitt’s lymphoma (3 pt), immunocytoma (2 pt), primary intestinal lymphoma (1 pt), hairy cell leukemia (1 pt), chronic lymphocytic leukemia (1 pt) and unclassified B-cell lymphoma (1 pt). No severe adverse events were observed during rituximab maintenance therapy. Results from an interim analysis including event free survival and overall survival for the observation group and for the maintenance therapy group will be presented. Conclusions: We conclude that rituximab maintenance therapy is feasable, effective, safe and well tolerated in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. No significant financial relationships to disclose.

Download Full-text